Injuries involving e-bikes and e-scooters are rising exponentially among children and teens, according to a new study out this week.

A study published yesterday found that injuries from e-bikes showed a roughly 400% relative increase from 2023 to 2026, and e-scooter injuries rose by almost 200%. A growing number of kids are landing in emergency rooms, hospitals, and urgent-care centers across the U.S. after riding e-scooters and e-bikes, TIME's Veronique Greenwood wrote in a new piece for the magazine.

Greenwood talked to doctors who are worried about kids on e-bikes and similar devices, and they shared advice on how to curb this growing problem.

The newsletter also addressed a reader's question about whether daily dips in scalding hot springs are safe. Research suggests hot-water immersion can be safe and even beneficial. In a hot tub or hot spring, your heart rate goes up, the pattern of blood flow through the body changes, and you might feel better mentally afterwards, said Christopher Minson, a professor of human physiology at the University of Oregon.

When you get out, "your blood pressure might be down for a few hours. Your insulin signaling might be improved for a while," he said. Social benefits may also come with visiting hot springs or public baths. "One thing I noticed in Japan, it was a meeting place for many older adults, and they talk about it preventing 'social frailty,'" said Brendon Roxburgh, a lecturer in clinical exercise physiology at the University of Otago in New Zealand.

That doesn't mean you should cook yourself. Places where many people engage in hot-water immersion, like Japan, also have higher rates of heat injury, particularly in older folks. "Older adults don't necessarily perceive the same degree of warmth or discomfort as younger people, even when their bodies are experiencing considerable heat exposure. This means they may not recognize when they are becoming excessively hot," Roxburgh said.

Separately, the U.S. Food and Drug Administration approved the first generic version of lenacapavir, the twice-a-year injection that prevents HIV. Made by Dr. Reddy's Laboratories of India, the shots would cost about $40 per person per year in eligible countries—comparable to the cost of daily HIV-prevention pills in those markets. Public-health experts, including those at Unitaid, hope broader access to the shots will prevent more HIV infections and ultimately reduce HIV-related deaths.

The drug's developer, Gilead, still holds the patent on the drug, which was approved for HIV prevention in 2025, but has issued licenses to six generic manufacturers to produce versions for low- and middle-income countries. A new KFF analysis also found U.S. health insurance premiums for people on Silver plans on the Affordable Care Act marketplace will increase 13% in 2027, marking the second consecutive year of double-digit increases.